AstraZeneca and Levi shares dropped after clinical trial setbacks and cautious guidance, overshadowing Ampco-Pittsburgh’s strong order growth.
AstraZeneca and Ionis Pharmaceuticals shares fell after their Phase 3 CARDIO-TTRansform trial for Wainua in ATTR-CM patients failed to meet its primary endpoint. The companies will conduct further data analysis following the disappointing results, which weighed on investor sentiment.
Levi Strauss shares declined as investors focused on a cautious full-year outlook and lower-than-expected EPS guidance. Despite strong Q2 revenue and earnings, concerns over tariff headwinds pressured the stock.
Ampco-Pittsburgh shares surged after reporting a 32% rise in H1 2026 customer orders and securing record air handling equipment orders. Strong demand across both operating segments drove the gain.